Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 123

Sort by

Sort Order Select

Journal Articles

Assessment of the prognostic value of FDG PET-derived markers and responses in POLARIX

Anne-Ségolène Cottereau, Alex Herrera, Hervé Tilly, Gilles Salles, Loïc Chartier, Matthew Sugidono, Skander Jemaa, Richard Carano, Connie Lee Batlevi, Greg Hapgood, Georg Lenz, Franck Morschhauser

Blood (2025) 146 (Supplement 1): 5329.

https://doi.org/10.1182/blood-2025-5329

Published: 2025

Journal Articles

Autologous and allogeneic stem cell transplantation for ALK-positive anaplastic large cell lymphoma: An analysis of the EBMT lymphoma working party

Evgenii Shumilov, Maud Ngoya, Philipp Berning, Irma Khvedelidze, Sridhar Chaganti, Regis Peffault De Latour, Kate Cwynarski, Laura Magnano, Frank Kroschinsky, Johannes Clausen, José Antonio Pérez-Simón, Lawrence Ng, Luca Castagna, Georg Lenz, Anna Sureda, Gandhi Damaj, Ali Bazarbachi, Norbert Schmitz

Blood (2025) 146 (Supplement 1): 891.

https://doi.org/10.1182/blood-2025-891

Published: 2025

Journal Articles

Prognostic role of FDG-PET in outcomes of relapsed/refractory large B-cell lymphoma treated with CD3-CD20 directed bispecific antibodies

Sophie Wollnitza, David Ventura, Marcel Teichert, Fabian Freisleben, Hristo Boyadzhiev, Robert Seifert, Michelle Amon, Julia Scholz, Alexander Pohlmann, Akhil Behringer, Philipp Backhaus, Philipp Schindler, Wolfgang Roll, Fabian Müller, Thomas Pabst, Michael Schaefers, Bastian von Tresckow, Evgenii Shumilov, Georg Lenz

Blood (2025) 146 (Supplement 1): 5518.

https://doi.org/10.1182/blood-2025-5518

Published: 2025

Journal Articles

Phase II frontline chemolight R-pola-glo trial induces high and durable response rates in elderly and medically unfit/frail patients with aggressive B-cell lymphoma

Blood (2025) 146 (Supplement 1): 61.

https://doi.org/10.1182/blood-2025-61

Published: 2025

Journal Articles

Identification of ferroptosis-sensitizers for DLBCL treatment

Rica Hagenbrock, Anja Schmitt, Jan Labisch, Hannah Junge, Nina Kreienkamp, Georg Lenz, Stephan Hailfinger

Blood (2025) 146 (Supplement 1): 3303.

https://doi.org/10.1182/blood-2025-3303

Published: 2025

Journal Articles

Impact of bridging therapy on efficacy of CD19 CAR T cell therapy in diffuse-large B cell lymphoma: Histology and the choice of drug matter

Blood (2025) 146 (Supplement 1): 1949.

https://doi.org/10.1182/blood-2025-1949

Published: 2025

Journal Articles

Real-world use of loncastuximab tesirine in heavily pretreated and high risk relapsed/refractory large B-cell lymphoma patients: German multicenter analysis

Evgenii Shumilov, Débora-Michèle Grote Urtubey, Marcel Teichert, Maximilian Seib, Rebecca Wurm-Kuczera, Joseph Kauer, Friedrich-Linus Roessiger, Tobias Tix, Alexander Hölscher, Philipp Gödel, Christoph Brey, Paolo Mazzeo, Zoi Saxonis, Belana Kuhn, Vanja Zeremski, Franziska Brunner, Susanne Ghandili, Enver Aydilek, Markus Maulhardt, Philipp Nakov, Gregor Friedrich, Christian Schultze-Florey, Giuliano Filippini Velazquez, Igor Age Kos, Anna Ossami Saidy, Christoph Kimmich, Maika Klaiber-Hakimi, Philipp Berning, Andrea Kerkhoff, Bertram Glass, Isabelle Krämer, Lorenz Thurner, Mathias Lutz, Florian Heidel, Vladan Vucinic, Christiane Pott, Andreas Viardot, Gerald Wulf, Thomas Weber, Dimitrios Mougiakakos, Francis Ayuk, Udo Holtick, Sascha Dietrich, Niklas Gebauer, Ulf Schnetzke, Mathias Hänel, Martin Dreyling, Peter Dreger, Björn Chapuy, Fabian Müller, Bastian von Tresckow, Georg Lenz

Blood (2025) 146 (Supplement 1): 5473.

https://doi.org/10.1182/blood-2025-5473

Published: 2025

Journal Articles

A first-in-human Phase 1 trial of LY4152199, a B-cell activation factor receptor (BAFF-R) T-cell engager bispecific antibody, in patients with previously treated B-cell malignancies (BAF_FRontier-1 Trial in Progress)

Krish Patel, Jennifer Crombie, Tycel Phillips, Michael Dickinson, Toby Eyre, Chan Cheah, Stephen Schuster, Nirav Shah, Georg Lenz, Laurie Sehn, Donald Tsai, Erica Johnston, Sonya Chapman, Hongmei Han, Minna Balbas, Ching Ching Leow, Gilles Salles

Blood (2025) 146 (Supplement 1): 5524.

https://doi.org/10.1182/blood-2025-5524

Published: 2025

Journal Articles

Efficacy and safety of vipor (P) in relapsed or refractory large B-cell lymphoma

Thomas Oellerich, Rebecca Wurm-Kuczera, Shashwat Sahay, Meng Wang, Salaheddine Ali, Nazli Serin, Khouloud Kouidri, Donika Tahiri, Sebastian Scheich, Uta Brunnberg, David Winkler, Samixa Pudasaini, Zoi Saxonis, Atef Abdelhafez, Tatiana Borodina, Ulrike Krueger, David Böckle, Corinna Leng, Joseph Kauer, Isabelle Krämer, Konstantinos Christofyllakis, Marcel Teichert, Niklas Gebauer, Ulf Schnetzke, Thomas Weber, Lukas Frenzel, Anna-Carina Hund, Evgenii Shumilov, Thomas Melchardt, Florian Eisele, Mirjeta Berisha, Jakob Rudzki, Christian Scholz, Martin Schmidt-Hieber, Dimitrios Mougiakakos, Johannes Duell, Gerald Wulf, Christian Schmidt, Georg Lenz, Bastian von Tresckow, Hans Christian Reinhardt, Richard Greil, Lorenz Thurner, Peter Dreger, Martin Dreyling, Christiane Pott, Martina Rudelius, Oliver Weigert, Phillipp Strubel, Roland Eils, Antonia Busse, Ulrich Keller, Naveed Ishaque, Björn Chapuy

Blood (2025) 146 (Supplement 1): 3688.

https://doi.org/10.1182/blood-2025-3688

Published: 2025

Journal Articles

Bridging to CD19 CAR T-cell therapy for LBCL: An analysis of 1,154 patients by the EBMT lymphoma working party and the gocart coalition

Blood (2025) 146 (Supplement 1): 5494.

https://doi.org/10.1182/blood-2025-5494

Published: 2025

Journal Articles

Multiple time-point FDG-PET imaging for risk stratification of patients with relapsed/refractory large B-cell lymphoma undergoing CD19-directed CAR-T cell therapy

Blood (2025) 146 (Supplement 1): 5491.

https://doi.org/10.1182/blood-2025-5491

Published: 2025

Journal Articles

A single-cell co-expression score of MYC and BCL2 identifies high-risk BCR-addicted DLBCL benefiting from polatuzumab vedotin in the POLARIX trial

Shruti Sridhar, Will Harris, Chartsiam Tipgomut, Qiang Pan-Hammarstrom, Gilles Salles, Alex Herrera, Marek Trneny, Franck Morschhauser, Connie Lee Batlevi, Matthew Sugidono, Yanwen Jiang, Georg Lenz, Anand Devaprasath Jeyasekharan

Blood (2025) 146 (Supplement 1): 3522.

https://doi.org/10.1182/blood-2025-3522

Published: 2025

Journal Articles

Transcriptional profiling refines DLBCL classification and identifies subtypes with distinct therapeutic vulnerabilities

James Godfrey, Sravya Tumuluru, Alan Cooper, Gilles Salles, Marek Trneny, Georg Lenz, Franck Morschhauser, Fabrice Jardin, Will Harris, Sandhya Balasubramanian, Matthew Sugidono, Connie Lee Batlevi, Yanwen Jiang, Justin Kline, Alex Herrera

Blood (2025) 146 (Supplement 1): 49.

https://doi.org/10.1182/blood-2025-49

Published: 2025

Journal Articles

Common hereditary variants of the APOE gene and posttransplant outcome in acute myeloid leukemia

Blood (2025) 145 (17): 1943–1956.

https://doi.org/10.1182/blood.2024026886

Published: 2025

Includes: Supplemental data

Journal Articles

SKYGLO: A Global Phase III Randomized Study Evaluating Glofitamab Plus Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients with Large B-Cell Lymphoma (LBCL)

Ranjana H. Advani, Michael J. Dickinson, Christopher P. Fox, Brad Kahl, Alex F. Herrera, Georg Lenz, Yuqin Song, Rong Tao, Qingqing Cai, Tae Min Kim, Michelle Doral, Derrick Kaufman, Leonardo Roque Pereira, Aurelien Berthier, Franck Morschhauser

Blood (2024) 144 (Supplement 1): 1718.1.

https://doi.org/10.1182/blood-2024-194000

Published: 2024

Journal Articles

Outcomes of Tagraxofusp in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Multicenter Real-World Analysis

Blood (2024) 144 (Supplement 1): 3818.

https://doi.org/10.1182/blood-2024-211227

Published: 2024

Journal Articles

Autologous Hematopoietic Stem Cell Transplantation in Natural Killer/T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party

Blood (2024) 144 (Supplement 1): 3070.

https://doi.org/10.1182/blood-2024-207545

Published: 2024

Journal Articles

Evaluation of Urine cfDNA for Non-Invasive Genomic Characterization in Multiple Myeloma: A Comparative Study with Serum and Bone Marrow Samples

Carl Jannes Neuse, Christoph Schliemann, Cyrus Khandanpour, Georg Lenz, Irene Ghobrial, Mark Bustoros

Blood (2024) 144 (Supplement 1): 7493.

https://doi.org/10.1182/blood-2024-210454

Published: 2024

Journal Articles

“As Treated” Validation of the European LeukemiaNet (ELN) Classification for Adult Acute Myeloid Leukemia (AML) Patients (pts) Treated in a Large AML-Referral Center from 2010-2022

Andrew F. Berdel, Julian Ronnacker, Daniela V. Wenge, Lina Kolloch, Philipp Berning, Linus Angenendt, Tobias Brix, Annette Westermann, Klaus Wethmar, Torsten Kessler, Andrea Kerkhoff, Rolf M. Mesters, Christian Reicherts, Jan-Henrik Mikesch, Wolfgang E. Berdel, Georg Lenz, Christoph Schliemann, Matthias Stelljes

Blood (2024) 144 (Supplement 1): 4242.

https://doi.org/10.1182/blood-2024-193666

Published: 2024

Journal Articles

Efficacy of Idecabtagene Vicleucel (ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma and Prior Central Nervous System Manifestation: A Retrospective Real-World Analysis

Blood (2024) 144 (Supplement 1): 4759.

https://doi.org/10.1182/blood-2024-202467

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Assessment of the prognostic value of FDG PET-derived markers and responses in POLARIX

Autologous and allogeneic stem cell transplantation for ALK-positive anaplastic large cell lymphoma: An analysis of the EBMT lymphoma working party

Prognostic role of FDG-PET in outcomes of relapsed/refractory large B-cell lymphoma treated with CD3-CD20 directed bispecific antibodies

Phase II frontline chemolight R-pola-glo trial induces high and durable response rates in elderly and medically unfit/frail patients with aggressive B-cell lymphoma

Identification of ferroptosis-sensitizers for DLBCL treatment

Impact of bridging therapy on efficacy of CD19 CAR T cell therapy in diffuse-large B cell lymphoma: Histology and the choice of drug matter

Real-world use of loncastuximab tesirine in heavily pretreated and high risk relapsed/refractory large B-cell lymphoma patients: German multicenter analysis

A first-in-human Phase 1 trial of LY4152199, a B-cell activation factor receptor (BAFF-R) T-cell engager bispecific antibody, in patients with previously treated B-cell malignancies (BAF_FRontier-1 Trial in Progress)

Efficacy and safety of vipor (P) in relapsed or refractory large B-cell lymphoma

Bridging to CD19 CAR T-cell therapy for LBCL: An analysis of 1,154 patients by the EBMT lymphoma working party and the gocart coalition

Multiple time-point FDG-PET imaging for risk stratification of patients with relapsed/refractory large B-cell lymphoma undergoing CD19-directed CAR-T cell therapy

A single-cell co-expression score of MYC and BCL2 identifies high-risk BCR-addicted DLBCL benefiting from polatuzumab vedotin in the POLARIX trial

Transcriptional profiling refines DLBCL classification and identifies subtypes with distinct therapeutic vulnerabilities

Common hereditary variants of the APOE gene and posttransplant outcome in acute myeloid leukemia

SKYGLO: A Global Phase III Randomized Study Evaluating Glofitamab Plus Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients with Large B-Cell Lymphoma (LBCL)

Outcomes of Tagraxofusp in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Multicenter Real-World Analysis

Autologous Hematopoietic Stem Cell Transplantation in Natural Killer/T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party

Evaluation of Urine cfDNA for Non-Invasive Genomic Characterization in Multiple Myeloma: A Comparative Study with Serum and Bone Marrow Samples

“As Treated” Validation of the European LeukemiaNet (ELN) Classification for Adult Acute Myeloid Leukemia (AML) Patients (pts) Treated in a Large AML-Referral Center from 2010-2022

Efficacy of Idecabtagene Vicleucel (ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma and Prior Central Nervous System Manifestation: A Retrospective Real-World Analysis

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only